Skip to content
← Full study record

NCT03673124 · OUTCOME

Objective Response Rate (ORR)

Ribociclib and Letrozole Treatment in Ovarian Cancer · Source last updated 2025-12-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
90% Confidence Interval
Time frame
Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months.

What was measured

ORR was defined as the percentage of participants in the analysis population who achieved a complete response or partial response, as assessed by RECIST 1.1.

Analysis population: Eligible participants who received any amount of protocol therapy

Groups in this outcome

Ribociclib and Letrozole

Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle in combination with Letrozole 2.5 mg administered orally daily for 28 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ribociclib and Letrozole49

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Ribociclib and Letrozole30.6Not reported19.943.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        19.9
        upper Limit
        43.2
        value
        30.6
denoms
  1. counts
    1. group Id
      OG000
      value
      49
    units
    Participants
description
ORR was defined as the percentage of participants in the analysis population who achieved a complete response or partial response, as assessed by RECIST 1.1.
dispersion Type
90% Confidence Interval
groups
  1. description
    Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle in combination with Letrozole 2.5 mg administered orally daily for 28 days.
    id
    OG000
    title
    Ribociclib and Letrozole
param Type
NUMBER
population Description
Eligible participants who received any amount of protocol therapy
reporting Status
POSTED
time Frame
Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months.
title
Objective Response Rate (ORR)
type
PRIMARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice